RIGL250117C25000
- 0.01
- 0.000.00%
Rigel Pharmaceuticals Newsroom
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients With Sickle Cell Disease
Improved Revenues Required Before Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock's 28% Jump Looks Justified
Kissei Pharmaceutical's Partner JW Pharmaceutical Gains Approval for Tavalisse in South Korea
The 18% Return This Week Takes Rigel Pharmaceuticals' (NASDAQ:RIGL) Shareholders One-year Gains to 56%
Rigel Pharmaceuticals To Present At J.P. Morgan Healthcare Conference; Webcast At 11:15 AM ET
Rigel Reports Q4 2024 Revenue Of $57.6M With TAVALISSE $31M, REZLIDHIA $7.4M, GAVRETO $8.1M; R289 Receives FDA Orphan Drug Status For MDS; 2025 Revenue Projected At $200M-$210M
Rigel Pharmaceuticals Sees 4Q Rev About $57.6M >RIGL
Express News | Rigel Pharmaceuticals Inc - Expects 2025 Revenue of $200-$210 Million
Express News | Rigel Provides Business Update and 2025 Outlook
Press Release: Rigel Provides Business Update and 2025 Outlook
Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289
Express News | Rigel Announces R289 Granted Orphan Drug Designation by the FDA for Mds
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Express News | Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dow Jumps Over 200 Points, Crude Oil Gains 1.5%
Is There An Opportunity With Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 40% Undervaluation?
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57